secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002863
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics: GOBLET Cohort 4 third-line anal cancer ORR 29%; median DOR ~17 months; files new patent application
--------------------------------------------------------------------------------

- GOBLET Cohort 4: 4/14 evaluable third-line anal cancer patients responded (ORR 29%), 2 CRs, 2 PRs; median DOR ~17 months vs historical ~10%.
- Second-line anal cancer: pelareorep + atezolizumab achieved 30% ORR (vs 13.8% standard of care), median DOR 15.5 months (vs 9.5 months).
- Company planning Type C meeting with FDA in Q1 2026 to discuss accelerated approval pathway for third-line anal cancer.
- Filed Track 1 patent application for pelareorep manufacturing; expects final USPTO action in Q3 2026; claims could extend to 2044.
- Additional patent applications planned for manufacturing and method-of-use to potentially extend coverage beyond 2044.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000110465926002863/0001104659-26-002863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000110465926002863/tm262940d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer